CMBA
PRVL

C.M. Bidwell & Associates’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

C.M. Bidwell & Associates’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,965
Closed -$29K – 531
2020
Q2 		$29K Buy
+1,965
New +$30.3K 0.03% 280

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

C.M. Bidwell & Associates's PRVL Position: Q3 2020 in Review

C.M. Bidwell & Associates sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q3 2020, closing a stake of 1,965 shares — an estimated $29K sold.

C.M. Bidwell & Associates first reported a position in PRVL in Q2 2020 and held it in 1 quarter. The position peaked at $29K in Q2 2020. 76 funds tracked by Wall St. Rank hold PRVL as of Q3 2020.

  • C.M. Bidwell & Associates reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,965 Prevail Therapeutics Inc. Common Stock shares in Q3 2020, an estimated $29K.
  • C.M. Bidwell & Associates first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Prevail Therapeutics Inc. Common Stock position peaked at $29K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q3 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2020, filed 13 Nov 2020.